keyword
MENU ▼
Read by QxMD icon Read
search

Breast cancer her2+ recurrence

keyword
https://www.readbyqxmd.com/read/29333901/her2-positive-bilateral-metachronous-primary-breast-carcinoma-a-case-report
#1
Jinghao Yao, Jing Liu, Yawei Li, Yumei Li, Qiong Wu, Yan Yang
Human epidermal growth factor receptor 2 (HER2) positive is a unique molecular subtype of breast cancer (BC) characterized by high malignancy and poor prognosis. Bilateral primary breast cancer (BPBC) harboring HER2 gene amplification is available to be detected among the BC survivors due to the increasing use of anti-HER2 adjuvant therapy. However, owing to the paucity of cases reported, knowledge of treating HER2-positive BPBC patients including the clinical behavior, histopathologic characteristics, anti-HER2 therapeutic response and disease outcome are not fully understood...
January 15, 2018: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/29327245/high-nuclear-msk1-is-associated-with-longer-survival-in-breast-cancer-patients
#2
Xuan Pu, Sarah J Storr, Narmeen S Ahmad, Emad A Rakha, Andrew R Green, Ian O Ellis, Stewart G Martin
PURPOSE: Mitogen- and stress-activated kinases (MSKs) are important substrates of the mitogen-activated protein kinase (MAPK)-activated protein kinase family. MSK1 and MSK2 are both nuclear serine/threonine protein kinases, with MSK1 being suggested to potentially play a role in breast cancer cell proliferation, cell cycle progression, cell migration, invasion and tumour growth. The aim of the current study was to assess MSK1 protein expression in breast cancer tumour specimens, evaluating its prognostic significance...
January 11, 2018: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/29326401/efficacy-and-tolerability-of-trastuzumab-emtansine-in-advanced-human-epidermal-growth-factor-receptor-2-positive-breast-cancer
#3
W Yeo, M Y Luk, I S Soong, T Ys Yuen, T Y Ng, F Kf Mo, K Chan, S Y Wong, J Tsang, C Leung, J Js Suen, R Kc Ngan
INTRODUCTION: The management of human epidermal growth factor receptor 2 (HER2)-positive breast cancer has changed dramatically with the introduction and widespread use of HER2-targeted therapies. There is, however, relatively limited real-world information about the effectiveness and safety of trastuzumab emtansine (T-DM1) in the Hong Kong Chinese patients. We assessed the efficacy and toxicity profiles among local patients with HER2-positive advanced breast cancer who had received T-DM1 therapy in the second-line setting and beyond...
January 12, 2018: Hong Kong Medical Journal, Xianggang Yi Xue za Zhi
https://www.readbyqxmd.com/read/29325268/-clinical-significance-of-targeting-drug-based-molecular-biomarkers-expression-in-ovarian-clear-cell-carcinoma
#4
M J Li, H R Li, X Cheng, R Bi, X Y Tu, F Liu, L H Chen
Objective: To assess the expression level of targeting drug-based molecular biomarkers in ovarian clear cell carcinoma (OCCC) tissues and its clinical significance. Methods: A total of 63 OCCC patients included 40 primary OCCC and 23 recurrent OCCC for secondary cytoreductive surgery (SCS), who had received primary surgeries at Fudan University Shanghai Cancer Center between January, 2008 and December, 2015 were enrolled, and immunohistochemistry SP method was used to test human epidermal growth factor receptor (EGFR), human epidermal growth factor receptor-2 (HER2), aurora kinase A (AURKA), breast cancer susceptibility gene 1 (BRCA1), BRCA2 and programmed death-ligand 1 (PD-L1)protein expression in paraffin-embedded tissues...
December 25, 2017: Zhonghua Fu Chan Ke za Zhi
https://www.readbyqxmd.com/read/29324312/the-hypoxia-responsive-long-non-coding-rnas-may-impact-on-the-tumor-biology-and-subsequent-management-of-breast-cancer
#5
REVIEW
Andrea Kapinova, Peter Kubatka, Pavol Zubor, Olga Golubnitschaja, Zuzana Dankova, Sona Uramova, Ivana Pilchova, Martin Caprnda, Radka Opatrilova, Jan Richnavsky, Peter Kruzliak, Jan Danko
Long non-coding RNAs (lncRNAs) are DNA transcripts longer than 200 nucleotides without protein-coding potential. As they are key regulators of gene expression at chromatic, transcriptional and posttranscriptional level, they play important role in various biological and pathological processes. Dysregulation of lncRNAs has been observed in several diseases including cancer. Breast cancer is heterogeneous disease with many molecular subtypes specific in different prognosis and treatment responses. Hypoxia, a common micro-environmental feature of rapidly growing tumour is associated with metastases, recurrences and resistance to therapy...
January 8, 2018: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/29321183/ptgs2-polymorphism-rs689466-favors-breast-cancer-recurrence-in-obese-patients
#6
Daniely Regina Freitas-Alves, Hayra de Andrade Vieira-Monteiro, Diogo Nascimento Piranda, Marcelo Sobral-Leite, Taiana Sousa Lopes da Silva, Anke Bergmann, Samuel Dos Santos Valença, Jamila Alessandra Perini, Rosane Vianna-Jorge
Breast cancer is the leading cancer among women, and its increasing incidence is a challenge worldwide. Estrogen exposure is the main risk factor, but obesity among postmenopausal women has been shown to favor disease onset and progression. The link between obesity and mammary carcinogenesis involves elevated estrogen production and pro-inflammatory stimuli within the adipose tissue, with activation of the cyclooxygenase-2 pathway. Here, we evaluate the impact of the four most common cyclooxygenase-2 gene polymorphisms (rs689465, rs689466, rs20417 and rs20417), in combination with obesity, on the risk of breast cancer progression in a cohort of Brazilian breast cancer patients (N = 1038)...
January 10, 2018: Endocrine-related Cancer
https://www.readbyqxmd.com/read/29316513/the-biology-of-male-breast-cancer
#7
REVIEW
Ian S Fentiman
Important differences have begun to emerge concerning the molecular profile of female and male breast cancer which may prove to be of therapeutic value. This review examined all the available data on the genomics of MBC. Most male cancers are ER+ve but without a corresponding increase in PR positivity and only a weaker association with estrogen-controlled markers such as PS2, HSP27 and Cathepsin-D. HER2 +ve cancers are rare in males and the role of androgen receptor is controversial. Although the Luminal A phenotype was the most frequent in both MBC and FBC, no Luminal B or HER2 phenotypes were found in males and the basal phenotype was very rare...
January 6, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29306660/clinical-impact-of-21-gene-recurrence-score-test-within-the-veterans-health-administration-utilization-and-receipt-of-guideline-concordant-care
#8
Leland E Hull, Julie A Lynch, Brygida B Berse, Scott L DuVall, Danielle S Chun, Vicki L Venne, Olga V Efimova, Michael S Icardi, Michael J Kelley
INTRODUCTION: Ensuring guideline-concordant cancer care is a Department of Veterans Affairs (VA) priority, especially as the number of breast cancer patients at VA medical centers (VAMCs) grows. We assessed the utilization and clinical impact of the 21-gene Recurrence Score test, which predicts 10-year risk of breast cancer recurrence and the likelihood of chemotherapy benefit, on veterans newly diagnosed with breast cancer. PATIENTS AND METHODS: We conducted a retrospective cohort study using 2011-2012 VA Central Cancer Registry, chart review, and laboratory test data...
November 29, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29305309/evaluation-of-prognosis-in-hormone-receptor-positive-her2-negative-and-lymph-node-negative-breast-cancer-with-low-oncotype-dx-recurrence-score
#9
Jane Meisel, Chao Zhang, Cameron Neely, Pia Mendoza, Shuo You, Tatiana Han, Yuan Liu, Aysegul A Sahin, Ruth O'Regan, Xiaoxian Li
INTRODUCTION: Hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancers without lymph node metastasis have good prognosis. We compared the prognosis of hormone receptor-positive, HER2-negative, lymph node-negative cancers with Oncotype DX score ranges of 1 to 10 (1-10 group) and 11 to < 18 (11-18 group). PATIENTS AND METHODS: A total of 107 cases in the 1-10 group and 225 cases in the 11-18 group were reviewed. All patients received surgery...
December 14, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29304773/breast-carcinoma-with-21-gene-recurrence-score-lower-than-18-rate-of-locoregional-recurrence-in-a-large-series-with-clinical-follow-up
#10
Gulisa Turashvili, Edi Brogi, Monica Morrow, Maura Dickler, Larry Norton, Clifford Hudis, Hannah Y Wen
BACKGROUND: The 21-gene recurrence score (RS) assay determines the benefit of adding chemotherapy to endocrine therapy for patients with early stage, estrogen receptor (ER)-positive, HER2-negative breast cancer. The RS risk groups predict the likelihood of distant recurrence and have recently been associated with an increased risk of locoregional recurrence (LRR). This study analyzed clinicopathologic features of patients with low RS and LRR. METHODS: In our institutional database, we identified 1396 consecutive female patients with lymph node negative, ER+/HER2- invasive breast carcinoma and low RS (<18) results, treated at our center from 2008 to 2013...
January 6, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29298305/response-monitoring-of-breast-cancer-patients-receiving-neoadjuvant-chemotherapy-using-quantitative-ultrasound-texture-and-molecular-features
#11
Lakshmanan Sannachi, Mehrdad Gangeh, Hadi Tadayyon, Ali Sadeghi-Naini, Sonal Gandhi, Frances C Wright, Elzbieta Slodkowska, Belinda Curpen, William Tran, Gregory J Czarnota
BACKGROUND: Pathological response of breast cancer to chemotherapy is a prognostic indicator for long-term disease free and overall survival. Responses of locally advanced breast cancer in the neoadjuvant chemotherapy (NAC) settings are often variable, and the prediction of response is imperfect. The purpose of this study was to detect primary tumor responses early after the start of neoadjuvant chemotherapy using quantitative ultrasound (QUS), textural analysis and molecular features in patients with locally advanced breast cancer...
2018: PloS One
https://www.readbyqxmd.com/read/29284000/oestrogen-receptor-negative-early-operable-primary-breast-cancer-in-older-women-biological-characteristics-and-long-term-clinical-outcome
#12
Binafsha Manzoor Syed, Dal Morgan, Tulassi Setty, Andrew R Green, Emma C Paish, Ian O Ellis, K L Cheung
BACKGROUND: Older women are at the greatest risk of breast cancer development and a considerable number present with comorbidities. Although the majority of breast cancers in this age group express oestrogen receptor (ER), which makes endocrine therapy (primary or adjuvant) feasible, given the huge size of the elderly population, there remains a significant number of patients, in absolute term, whose tumours do not express ER and their management is challenging. METHODS: Of a consecutive series of 1,758 older (≥70 years) women with early operable primary breast cancer managed in a dedicated service from 1973-2010, 252(14...
2017: PloS One
https://www.readbyqxmd.com/read/29282021/prediction-of-survival-after-neoadjuvant-chemotherapy-for-breast-cancer-by-evaluation-of-tumor-infiltrating-lymphocytes-and-residual-cancer-burden
#13
Yuka Asano, Shinichiro Kashiwagi, Wataru Goto, Koji Takada, Katsuyuki Takahashi, Takaharu Hatano, Satoru Noda, Tsutomu Takashima, Naoyoshi Onoda, Shuhei Tomita, Hisashi Motomura, Masahiko Ohsawa, Kosei Hirakawa, Masaichi Ohira
BACKGROUND: The tumor immune environment not only modulates the effects of immunotherapy, but also the effects of other anticancer drugs and treatment outcomes. These immune responses can be evaluated with tumor-infiltrating lymphocytes (TILs), which has frequently been verified clinically. On the other hand, residual cancer burden (RCB) evaluation has been shown to be a useful predictor of survival after neoadjuvant chemotherapy (NAC). In this study, RCB and TILs evaluations were combined to produce an indicator that we have termed "RCB-TILs", and its clinical application to NAC for breast cancer was verified by subtype-stratified analysis...
December 28, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29277761/antitumor-effects-of-lidocaine-on-human-breast-cancer-cells-an-in-vitro-and-in-vivo-experimental-trial
#14
Thiên-Nga Chamaraux-Tran, Carole Mathelin, Marc Aprahamian, Girish P Joshi, Catherine Tomasetto, Pierre Diemunsch, Cherif Akladios
AIM: Retrospective studies have suggested a protective effect of regional anesthesia against recurrence after cancer surgery. But confirmation of the in vivo antitumor effects is lacking. We examined the in vitro antitumor effects of lidocaine on various breast cancer cell lines and then assessed these properties in vivo at clinically relevant concentrations. MATERIALS AND METHODS: In vitro experiments: normal breast epithelial cells (NBEC) MCF-10A and three tumor breast epithelial cells (TBEC) lines (MCF-7 luminal A, MDA-MB-231 triple-negative and SKBr3 HER2 positive) were exposed to increasing concentrations of lidocaine...
January 2018: Anticancer Research
https://www.readbyqxmd.com/read/29274928/optimal-adjuvant-endocrine-treatment-of-er-her2-breast-cancer-patients-by-age-at-diagnosis-a-population-based-cohort-study
#15
G M H E Dackus, K Jóźwiak, G S Sonke, E van der Wall, P J van Diest, M Hauptmann, S Siesling, S C Linn
BACKGROUND: Prior randomised controlled trials on adjuvant hormonal therapy included HER2any patients; however, a differential effect of aromatase inhibitors (AIs) versus tamoxifen (TAM) may have been missed in ER+/HER2+ patients that comprise 7-15% of all breast cancer patients. In addition, a woman's hormonal microenvironment may influence sensitivity to TAM and AIs in the adjuvant setting, which changes during menopausal transition, a process that takes years. We studied the efficacy of AIs versus TAM in ER+/HER2+ breast cancer patients grouped by age at diagnosis as a proxy for menopausal status using treatment and outcome data from the nationwide population-based Netherlands Cancer Registry (NCR)...
December 21, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29261249/real-world-economic-value-of-a-21-gene-assay-in-early-stage-breast-cancer
#16
Stanley E Waintraub, Donna McNamara, Deena Mary Atieh Graham, Andrew L Pecora, John Min, Tommy Wu, Hyun Gi Noh, Jacqueline Connors, Ruth Pe Benito, Kelly Choi, Eric Schultz, Stuart L Goldberg
OBJECTIVES: Value-based payment reforms shift cost-containment responsibilities to the physician. Although gene expression profiling (GEP) utilizing a 21-gene panel among patients with early-stage, axillary lymph node-negative, hormone receptor-positive, HER2/neu oncogene-negative breast cancer is able to identify a cohort that may achieve excellent outcomes without adjuvant chemotherapy, high up-front costs (list price, $4175) could dissuade usage. STUDY DESIGN: Retrospective review of consecutive patients with breast cancer treated at a single cancer center...
December 1, 2017: American Journal of Managed Care
https://www.readbyqxmd.com/read/29250179/no-association-between-triple-negative-breast-cancer-and-prognosis-of-patients-receiving-breast-conserving-treatment
#17
Lan Mu, Yuxiang Liu, Meng Xiao, Weise Liu, Miao Liu, Xin Wang
The role of triple-negative breast cancer (TNBC) in breast-conserving treatment is controversial. The present study aimed at evaluating the prognosis of patients with TNBC following breast-conserving treatment (BCT) within 5 years. The present study investigated a cohort of 757 patients with early stage breast cancer, diagnosed and treated with BCT between January 2002 and March 2010 at Tianjin Medical University Cancer Institute and Hospital. The patients were divided into three groups according to receptor expression: Estrogen receptor (ER) or progesterone receptor (PR)-positive; epidermal growth factor receptor 2 (HER2)-enriched: ER and PR negative but HER2-positive; TNBC: ER, PR and HER2 receptor-negative...
December 2017: Oncology Letters
https://www.readbyqxmd.com/read/29237612/ctcs-may-predict-breast-cancer-recurrence
#18
(no author information available yet)
Findings from a prospective study indicate that for patients diagnosed with ER-positive, HER2-negative breast cancer, the presence of circulating tumor cells several years afterward considerably ups the risk-by nearly 22-fold-of their disease making a late reappearance.
December 13, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/29207087/p-stat3-in-luminal-breast-cancer-integrated-rna-protein-pooled-analysis-and-results-from-the-big-2-98-phase-iii-trial
#19
Amir Sonnenblick, Roberto Salgado, Sylvain Brohée, Tamar Zahavi, Tamar Peretz, Gert Van den Eynden, Ghizlane Rouas, Asher Salmon, Prudence A Francis, Angelo Di Leo, John P A Crown, Giuseppe Viale, Laura Daly, Bahar Javdan, Sho Fujisawa, Evandro De Azambuja, Ameye Lieveke, Martine J Piccart, Jacqueline F Bromberg, Christos Sotiriou
In the present study, in order to investigate the role of signal transducer and activator of transcription 3 (STAT3) in estrogen receptor (ER)-positive breast cancer prognosis, we evaluated the phosphorylated STAT3 (p-STAT3) status and investigated its effect on the outcome in a pooled analysis and in a large prospective adjuvant trial. By using the TCGA repository, we developed gene signatures that reflected the level of p-STAT3. Using pooled analysis of the expression data from luminal breast cancer patients, we assessed the effects of the p-STAT3 expression signature on prognosis...
November 27, 2017: International Journal of Oncology
https://www.readbyqxmd.com/read/29202609/the-ability-of-pam50-risk-of-recurrence-score-to-predict-10-year-distant-recurrence-in-hormone-receptor-positive-postmenopausal-women-with-special-histological-subtypes
#20
Anne-Vibeke Laenkholm, Maj-Britt Jensen, Jens Ole Eriksen, Wesley Buckingham, Sean Ferree, Torsten O Nielsen, Bent Ejlertsen
INTRODUCTION: The Prosigna-PAM50 risk of recurrence (ROR) score has been validated in randomized clinical trials to predict 10-year distant recurrence (DR) in hormone receptor-positive breast cancer. Here, we examine the ability of Prosigna for predicting DR at 10 years in a subgroup of postmenopausal breast cancer patients with special histological subtypes. METHODS: Using the population based Danish Breast Cancer Group database, follow-up data were collected on all patients diagnosed from 2000 to 2003 with estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2) normal breast cancer who by nationwide guidelines were treated with 5 year of endocrine therapy (N = 2558)...
January 2018: Acta Oncologica
keyword
keyword
115348
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"